August J Moretti
CIK 1344412 · Chief Financial Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$108.8K
Companies
5
Total Filings
59
Lifetime Open-Market Net
-$1.06M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VANI | Director | — | $1.31 | — | $0 | 1 | 2026-06-26 |
| CBUS | Director | — | $1.94 | — | $0 | 3 | 2026-06-04 |
| FDMT | Chief Financial Officer | 11,045 | $9.85 | $108.8K | $0 | 7 | 2023-05-16 |
| Assertio Therapeutics, Inc (DEPO) Delisted | Chief Financial Officer & SVP | 74,447 | — | — | -$681.1K | 21 | 2018-04-03 |
| Alexza Pharmaceuticals Inc. (ALXA) Delisted | SVP, CFO, GC & Sec | 9,942 | — | — | -$382.7K | 27 | 2011-08-01 |
Recent Filings · Page 2 of 6
59 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-03-10 | FDMT | Grant (A) | — | $0 | EDGAR |
| 2018-04-03 | Assertio Therapeutics, Inc (DEPO) Delisted | Tax (F) | −6,975 | -$46.0K | EDGAR |
| 2017-12-20 | Assertio Therapeutics, Inc (DEPO) Delisted | Disp (D) | — | $0 | EDGAR |
| 2017-12-05 | Assertio Therapeutics, Inc (DEPO) Delisted | Tax (F) | −10,336 | -$73.5K | EDGAR |
| 2017-04-04 | Assertio Therapeutics, Inc (DEPO) Delisted | Mixed | −940 | -$11.8K | EDGAR |
| 2017-02-10 | Assertio Therapeutics, Inc (DEPO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-06 | Assertio Therapeutics, Inc (DEPO) Delisted | Tax (F) | −10,853 | -$201.3K | EDGAR |
| 2016-11-15 | Assertio Therapeutics, Inc (DEPO) Delisted | Mixed | — | -$40.8K | EDGAR |
| 2016-08-11 | Assertio Therapeutics, Inc (DEPO) Delisted | Mixed | −1,703 | -$65.2K | EDGAR |
| 2016-05-09 | Assertio Therapeutics, Inc (DEPO) Delisted | Sell (S) | −5,000 | -$90.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.